查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133515

放射性药物全球市场-2022-2029

Global Radiopharmaceuticals Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

放射性药物市场的增长是由癌症和神经系统疾病等各种疾病的发病率上升、放射性药物在疾病诊断和治疗中的应用增加、人口老龄化加剧以及研发活动推动的。 .

放射性药物的产品开发不断增加，预计将推动市场增长。

癌症和心血管疾病等疾病的患病率上升预计将在预测期内提振市场。根据美国国家癌症研究所 2020 年 10 月的数据报告，研究人员目前正在设计和测试各种癌症的放射性药物，包括肺癌、黑色素瘤、结肠癌和白血病。我们还重复使用橹 Lu 177 等目标分子来携带更有效的放射性化合物和同位素。例如，前列腺癌一直是这种重新利用的早期试验场。 PSMA 在前列腺细胞中含量丰富，其中大部分仅存在于前列腺细胞中。通过将与 PSMA 结合的分子与放射性化合物融合，它可用于通过 PET 扫描进行诊断成像。

此外，将放射性药物与其他治疗结合使用可能是促进其改善的一种方法。一些研究人员现在正在测试放射性药物与放射增敏剂（使癌细胞更容易受到辐射的药物）的组合。例如，在临床试验中，橹 Lu177 dotatate 和放射增敏剂 Triapine 的组合可抑制细胞在放射损伤后产生 DNA 修復所需的化合物。

放射性药物治疗的缺点阻碍了市场增长

然而，放射性药物治疗的缺点包括辐射风险、非疾病特异性成像，因为这种治疗通常需要注射到血液中、放射性废物的处理以及治疗成本高等等。这些因素都在抑制市场的增长。

COVID-19 影响分析

COVID-19 的出现对全球放射性药物市场产生了相当大的影响。冠状病毒 19 病 (COVID-19) 大流行无疑给全球医疗保健系统带来了重大挑战。辉瑞在一份声明中表示，COVID-19 对癌症患者的最大影响之一是暂停手术和临床试验引起的恐惧。 2020 年 4 月，英国癌症研究委员会报告称，全英国每週接受肠癌、乳腺癌和宫颈癌筛查的人数比大流行前减少了约 20 万人，并且诊断出大量早期癌症。 .放疗疗程也明显减少，2020 年 4 月减少近 20%，5 月减少 6.2%，6 月减少 11.6%，与 2019 年同月相比。

此外，即使在大流行期间，一些组织也在进行研究。例如，癌症研究所 (CRI) 报告了对在世界各地机构进行癌症临床试验的 36 名研究人员的调查结果。到 2022 年，情况正在从 COVID-19 中恢復，患者可以获得适当的治疗，从而导致全球放射性药物治疗的市场增长。

全球放射性药物市场报告将提供对大约 65 多个市场数据表、65 多个数字和 200 多页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 癌症和心血管疾病的高发率
      • 对传染病措施的需求增加
    • 约束因素
      • 放射性药物的半衰期短
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第7章放射性同位素

  • Tech99
  • F18
  • 碘 131
  • 橹 177
  • 钇90
  • 镓-68
  • 镓-67
  • 铷 82
  • 碘 123
  • 碘 125
  • 铟 111
  • 其他

第 8 章. 按应用程序

  • 肿瘤学
  • 循环区
  • 肠胃科
  • 神经内分泌学
  • 神经内科
  • 神经内科
  • 其他

第九章来源

  • 迴旋加速器
  • 核反应堆

第 10 章，最终用户

  • 医院
  • 影像诊断中心
  • 门诊手术中心
  • 癌症研究所

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 13 章公司简介

  • Siemens AG
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Positron Corporation
  • Curium
  • GE Healthcare
  • Lantheus Holdings Inc.
  • Sotera Health LLC
  • Bayer AG
  • Eckert & Ziegler
  • Novartis AG
  • BWX Technologies Inc.

第 14 章全球放射性药物市场-DataM

简介目录
Product Code: DMPH562

Market Overview

Radiopharmaceuticals Market size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 6.2% over the forecast period 2022 to 2029.

Radiopharmaceuticals contain radioactive substances used to diagnose or treat diseases, including cancer or cardiology. These are used for the diagnosis of abscess and infection, blood vessel diseases, bone diseases, colorectal disease and others.

Market Dynamics

The radiopharmaceuticals market growth is driven by the rise in prevalence of different diseases such as cancer, and neurological disorders, rising adoption of radiopharmaceuticals for diagnosis and treatment of diseases, increase in the geriatric population, and research and development activities.

The rising product development in radiopharmaceutical is expected to drive the market growth

The rising prevalence of diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. According to the National Cancer Institute October 2020 data report, researchers have recently designed and tested radiopharmaceuticals for various cancers as diverse as lung, melanoma, colorectal, and leukemia. Also, researchers have repurposed, such as Lutetium Lu 177, targeting molecules to carry more potent radioactive compounds, or isotopes, instead ones that could kill cancer cells instead of simply helping visualize them. For instance, prostate cancer has been an early testing ground for this repurposing. PSMA is found in large amounts and almost exclusively on prostate cells. Fusing a molecule that binds PSMA to a radioactive compound is used in PET scan imaging.

Moreover, using radiopharmaceuticals in combination with other therapies may be one way to drive that improvement. Some researchers are now testing radiopharmaceuticals combined with radiation sensitizers-drugs that make cancer cells even more vulnerable to radiation. For example, a clinical trial of lutetium Lu 177-dotatate combined with a radiation sensitizer called triapine, blocks cells from producing the compounds needed for DNA repair after radiation-induced damage.

The disadvantages of radiopharmaceuticals therapy will hamper the growth of the market

However, the disadvantages of radiopharmaceutical therapy include radiation risks, images that are not usually disease-specific, in this therapy typically requiring injection into the bloodstream, disposal of radioactivity waste and high cost of the treatment. These factors are restraining the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global radiopharmaceuticals market. The coronavirus-19 disease (COVID-19) pandemic has undoubtedly posed significant challenges to healthcare systems globally. According to a statement by Pfizer, one of the greatest effects of COVID-19 on cancer patients is fear due to surgery and clinical trial disruptions. In addition, Cancer Research UK reported in April 2020 that a considerable number of early cancers would go undiagnosed, as there was a significant reduction in the number of people being screened for bowel, breast and cervical cancer across the UK, approximately 200,000 fewer per week than before the pandemic. There was also a significant decrease in radiotherapy treatment courses, nearly 20 % in April 2020, 6.2 % in May and 11.6 % in June, compared to the same months in 2019.

In addition, some organizations are conducting their studies even during a pandemic. For instance, the Cancer Research Institute (CRI) reported the results of a survey of 36 investigators conducting cancer clinical trials at institutions around the world. In 2022 situation is recovering from COVID-19, and the patient can access the proper treatments, leading to market growth of radiopharmaceutical therapy worldwide.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment is expected to boost the market throughout the forecast. The article was published in Future Oncology in June 2020; reported that, as per the WHO, worldwide cancer cases are predicted to increase around 60%, from 18.1 million in 2018 to 29.4 million by 2040. Also, as per the article published in Nature Reviews Drug Discovery in July 2020, several radiopharmaceutical therapy (RPT) agents are currently on the market, with many more in development. For instance, Bayer is developing Radium-223 chloride for Bone metastasis, Novartis is developing 177Lu-labelled DOTATATE for Neuroendocrine tumors, and Telix Pharma developing 211At-labelled aLAT-1a for Multiple myeloma. These include four B-particle and five α-particle emitters. Lead-212 decays to bismuth-212 and is used to deliver 212Bi, an α-emitter, without being constrained by its 1-hour half-life. Of the 30 RPT agents mentioned in the article, 13 deliver radionuclides that decay by α-particle emission. The interest in α-emitters reflects a potential growth area in RPT. The development of the RPT is increasing as the incidence and demand for treatment are rising, leading to the oncology segment growth in the market.

Geographical Analysis

North America region holds the largest market share of the global radiopharmaceuticals market

North America dominates the radiopharmaceutical market and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to rising cancer and another disease, advanced healthcare, launching new products and the presence of many key players. In July 2022, according to the Centers for Disease Control and Prevention, About 20.1 million adults age 20 and older have CAD (about 7.2%). With the rising incidence of disease, there is a demand for suitable treatment in the North American region.

In addition, the key players are adopting market strategies to expand their business. For instance, in November 2020, Canadian radiopharmaceuticals leading company Fusion Pharmaceuticals collaborated with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Also, in July 2022, PETNET Solutions Inc., a Siemens Healthineers company and the leading manufacturer of radiopharmaceuticals for positron emission tomography (PET) imaging in the United States, opened a new radiopharmacy in Florida, United States.

Competitive Landscape

The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens AG, Positron Corporation, Curium, GE Healthcare, Lantheus Holdings Inc., Sotera Health LLC, Bayer AG, Eckert & Ziegler, Novartis AG, and BWX Technologies Inc. among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.

For instance,

  • In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.

Novartis AG

Overview:

Novartis AG is a Swiss-American multinational pharmaceutical company founded in 1996 and headquartered in Switzerland. The company offers radiopharmaceutical products, including gallium Ga 68, for treating diseases such as cancer, cardiology, neurology and infectious & inflammatory diseases.

Product Portfolio:

PLUVICTO: The PLUVICTO brand name for lutetium Lu 177 vipivotide tetraxetan is used for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

The global radiopharmaceuticals market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High prevalence of cancer and cardiovascular disease
      • 4.1.1.2. Rising demand for infection control measure
    • 4.1.2. Restraints:
      • 4.1.2.1. The short half-life of radiopharmaceuticals
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Radioisotopes

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes Segment
    • 7.1.2. Market Attractiveness Index, By Radioisotopes Segment
  • 7.2. Tec.99 *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. F18
  • 7.4. Iodine 131
  • 7.5. Lutetium 177
  • 7.6. Yttrium 90
  • 7.7. Gallium 68
  • 7.8. Gallium 67
  • 7.9. Rubidium 82
  • 7.10. Iodine 123
  • 7.11. Iodine 125
  • 7.12. Indium 111
  • 7.13. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Oncology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Cardiology
  • 8.4. Gastroenterology
  • 8.5. Neuroendocrinology
  • 8.6. Neurology
  • 8.7. Nephrology
  • 8.8. Others

9. By Source

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 9.1.2. Market Attractiveness Index, By Source
  • 9.2. Cyclotrons *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nuclear Reactor

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Cancer Research Institute

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. Siemens AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Positron Corporation
  • 13.3. Curium
  • 13.4. GE Healthcare
  • 13.5. Lantheus Holdings Inc.
  • 13.6. Sotera Health LLC
  • 13.7. Bayer AG
  • 13.8. Eckert & Ziegler
  • 13.9. Novartis AG
  • 13.10. BWX Technologies Inc.

LIST NOT EXHAUSTIVE

14. Global Radiopharmaceuticals market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us